Analysis of risk factors for early progression of prostate cancer after initial endocrine therapy

Author:

Hu Bowen1ORCID,Shu Feng1,Liu Yan1,Zhu Jiaying2,Wang Haojie1,Xie Nengqing1,Liu Xiaoling1,Jiang Guanmin1,Yan Minbo1,Dai Yingbo1

Affiliation:

1. Fifth Affiliated Hospital of Sun Yat-sen University

2. Inner Mongolia Medical University

Abstract

AbstractProlonged androgen deprivation therapy (ADT) in patients with prostate cancer can eventually lead to the development of castration-resistant prostate cancer (CRPC). Once CRPC occurs, the patient's prognosis will be extremely poor. This study explored the time to progression and the predictability of risk factors for CRPC progression based on clinical information and laboratory indicators. Among 159 prostate cancer patients initially treated with ADT, 90 patients were screened for inclusion. Patients progressed to CRPC after endocrine therapy enrolled in Group B, and others enrolled in Group A. Within Group B, they were divided into B1 and B2 Group Based on progression to CRPC within 18 months or not. Multi-factor logistic regression analysis showed that the time to PSA nadir (TTN) (P = 0.031) and serum lactate dehydrogenase (LDH) (P = 0.013) were significantly different between Group A and B. TTN (P < 0.001), LDH (P = 0.001) and platelet to lymphocyte ratio (PLR) (P = 0.005) were significantly different between Group B1 and B2. Kaplan-Meier survival analysis and log-rank tests showed that TTN, LDH and PLR were statistically significantly different in CRPC progression-free survival. The ROC curve showed that the predictive value of TTN (AUC 0.852) (95% CI 0.768–0.942, p < 0.001) was much higher than that of PLR (AUC 0.631) or LDH (0.647) and that the AUC value of TTN combined with PLR and LDH increased to 0.958 (95% CI 0.911–0.997, p < 0.001). In addition, TTN correlated with tumour M-stage and haemoglobin (Hb). In conclusion, we derived independent and combined predictors of early progression to CRPC in prostate cancer patients.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3